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Activation of NF-kB following genotoxic
stress allows time for DNA-damage repair
and ensures cell survival accounting for ac-
quired chemoresistance, an impediment to
effective cancer therapy. Despite this clini-
cal relevance, little is known about path-
ways that enable genotoxic-stress-induced
NF-kB induction. Previously, we reported
a role for the p53-inducible death-domain-
containing protein, PIDD, in caspase-2 acti-
vation and apoptosis in response to DNA
damage. We now demonstrate that PIDD
plays a critical role in DNA-damage-induced
NF-kB activation. Upon genotoxic stress,
a complex between PIDD, the kinase RIP1,
and a component of the NF-kB-activating
kinase complex, NEMO, is formed. PIDD ex-
pression enhances genotoxic-stress-induced
NF-kB activation through augmented su-
moylation and ubiquitination of NEMO.
Depletion of PIDD and RIP1, but not cas-
pase-2, abrogates DNA-damage-induced
NEMO modification and NF-kB activation.
We propose that PIDD acts as a molecular
switch, controlling the balance between
life and death upon DNA damage.
INTRODUCTION
Although the transcription factor NF-kB is mainly associated
with its pivotal role in immune and inflammatory responses, it
has been known for a long time that NF-kB is also induced
by ‘‘noninflammatory’’ activators such as oxidative or geno-
toxic stress (Pahl, 1999). Indeed, DNA-damage-induced NF-
kB activation controls the transcription of cell survival genes,
allowing cells to escape the otherwise lethal effect of DNA
damage and to initiate pathways of DNA repair. In thisCellregard, activation of NF-kB by chemotherapeutic com-
pounds accounts for the phenomenon of acquired chemo-
resistance that impedes effective cancer therapy (Baldwin,
2001). Despite this notable clinical relevance, little is known
about the pathways enabling genotoxic-stress-induced
NF-kB induction.
NF-kB is a dimeric transcription factor composed ofmem-
bers of the Rel family, themost abundant dimer in the cell be-
ing RelA/p50 (for a recent review, see Hayden and Ghosh,
2004). In unstimulated cells, NF-kB is sequestered in the cy-
toplasm through interaction with an inhibitory protein, IkB,
which masks its nuclear localization signal. Almost all activa-
tors of NF-kB converge on the release of IkB through activa-
tion of an IkB kinase (IKK) complex that induces IkB
phosphorylation. This targets IkB for ubiquitination and sub-
sequent degradation, allowing freed NF-kB to translocate to
the nucleus and activate transcription of target genes. The
IKK complex is composed of two related kinases, IKKa
and IKKb, and a regulatory scaffolding subunit, NEMO
(alternatively called IKKg). During the past years, numerous
groups have contributed to our understanding of cell-
surface-receptor-induced NF-kB activation, unraveling for
example themain signaling pathways emanating from the tu-
mor necrosis factor (TNF) receptor family or the interleukin-
1/Toll-like receptor (TLR) family (Bonizzi and Karin, 2004).
Far less understood are the so-called ‘‘nuclear-to-cyto-
plasmic’’ pathways that trigger NF-kB activation, such as
those activated by DNA damage. The nature of the signaling
cascade initiated appears to depend strongly on the geno-
toxic stimulus and cell type used as well as on dose and tim-
ing of the stimulus, giving rise to many discrepancies in the
literature and hindering the emergence of a general model.
In spite of this, some of the key events have been identified.
With the exception of UV irradiation, which appears to in-
duce an entirely unrelated pathway (Kato et al., 2003),
most DNA-damage-inducing signals converge at the level
of the phosphorylation of cytoplasmic IkB through activation
of the IKK complex, similar to the classical activation of NF-
kB (e.g., (Huang et al., 2000; Hur et al., 2003)). The activation
of the IKK complex in response to irradiation or topoisomer-
ase I- or II-targeting drugs is strictly dependent on the pres-
ence of the nucleus and the formation of double strand
breaks, showing the intimate link between the presence of
DNA lesions and NF-kB activation and suggesting that123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1079
NF-kB activation forms part of a general cellular response in-
duced upon DNA damage (Boland et al., 2000; Huang et al.,
2000). A central component of the DNA-damage response is
the PI3-like kinase ATM (for ataxia telangiectasia mutated)
that is rapidly phosphorylated upon DNA double-strand
break (DSB) formation and in this way acts as a sensor of
chromatin alterations. ATM mounts a decisive, meticulously
orchestrated response through phosphorylation of several
key targets implicated in cell cycle control, DNA repair or
stress responses (for a review see Shiloh, 2003). ATM-defi-
cient cells from patients with the genomic instability disorder
ataxia telangiectasia are no longer able to activate NF-kB in
response to ionizing irradiation or treatment with the topoiso-
merase I poison camptothecin (CPT), indicating that ATM
also plays a pivotal role in activation of NF-kB (Li et al.,
2001; Piret et al., 1999). Supposedly, ATM directly phos-
phorylates IkB, based on in vitro assays (Jung et al., 1997),
but this has never been confirmed in vivo and, until recently,
ATM’s target substrate in the NF-kB pathway remained
obscure.
A major breakthrough was recently provided by the group
of Miyamoto (Huang et al., 2003), who demonstrated that
ATM is needed for ubiquitination of NEMO. In response to
DNA damage, NEMO appears to translocate to the nucleus
and undergo a series of posttranslational modifications (sub-
sequently sumoylation, phosphorylation, and ubiquitination),
which allows NEMO to be activated and be released from the
nucleus again, providing a means to link nuclear DNA dam-
age to the activation of the cytoplasmic IKK complex. ATM is
not needed for NEMO sumoylation, however, leaving the ini-
tial signal leading to nuclear translocation of NEMO and its
SUMO modification unidentified.
Sumoylation or the posttranslational modification of pro-
teins through covalent attachment with the small ubiquitin-
related protein SUMO is emerging as an important regulatory
mechanism that affects protein function through altered in-
teraction properties, retargeting of modified proteins to spe-
cific subcellular compartments, or by antagonizing other
modifications that occur at the same lysine (Hay, 2005; See-
ler and Dejean, 2003). Sumoylation occurs in a way that is
highly analogous to ubiquitination. Four subsequent enzy-
matic reactions lead to the maturation of SUMO; its activa-
tion through linkage via a thioesther bond with the E1 en-
zyme UBA2/Aos; its conjugation to the E2 enzyme Ubc9;
and, finally, its ligation to its target, which might occur in an
E3-independent way or by means of E3 ligases such as
members of the PIAS (protein inhibitor of activated STATs)
family, RanBP2, or polycomb protein Pc2 (Johnson and
Gupta, 2001; Kagey et al., 2003; Pichler et al., 2002).
Reminiscent of the caspase-9 apoptosome complex, cas-
pase-2 has been shown to form a high-molecular-weight
complex in cell extracts, albeit independently from Apaf or
cytochrome c (Read et al., 2002). We demonstrated previ-
ously that recruitment and activation of caspase-2 within
this complex is entirely dependent on the presence of RAIDD
and the p53-inducible protein PIDD, which together with
caspase-2 constitute the so-called PIDDosome (Tinel and
Tschopp, 2004). PIDD contains a C-terminal death domain
(DD) through which it recruits RAIDD; N-terminal leucine-1080 Cell 123, 1079–1092, December 16, 2005 ª2005 Elsevier Irich repeats (LRRs), probably involved in the recognition of
a stress-related signal of unknown nature; and two internal
ZU5 domains, which, together with the region in between
the ZU5 and the DD, are most likely implicated in PIDD olig-
omerization. Although the full-length protein has a molecular
mass of approximately 100 kDa, both endogenous and
overexpressed PIDD are constitutively processed at two
sites, giving rise to a 48 kDa N-terminal fragment and a C-
terminal fragment of 51 kDa, which is further cleaved, result-
ing in a 37 kDa fragment (Telliez et al., 2000; Tinel and
Tschopp, 2004).
Activation of the PIDDosome sensitizes cells to genotoxic-
stress-induced apoptosis (Tinel and Tschopp, 2004). In
addition to DNA damage, however, lysis of cells under
hypotonic conditions can also initiate assembly of the
PIDDosome. In the present work, we observed that PIDD
interacts with NEMO and RIP1 under these in vitro condi-
tions, motivating us to investigate whether the PIDDosome
might be implicated in the activation of NF-kB as well. We
will demonstrate a critical role for PIDD in DNA-damage-
induced activation of NF-kB and, more specifically, in the
pathway leading to SUMO modification of NEMO.
RESULTS
The PIDDosome Incorporates NF-kB
Signaling Components
Assembly and activation of the PIDDosome can be initiated
in vitro by lysing PIDD-expressing cells under hypotonic con-
ditions at 4ºC, followed by incubation at 37ºC. This results in
the recruitment of caspase-2 to PIDD via RAIDD (Figure 1; Ti-
nel and Tschopp, 2004). In order to further dissect the com-
position of the PIDDosome, we analyzed the complex for the
possible presence of another death-domain protein, RIP1,
which has been linked previously to genotoxic-stress-induced
signaling (Hur et al., 2003). The RIP1 kinase is a crucial com-
ponent of several signaling pathways that activate NF-kB,
such as those emanating from TNF receptors (TNF-R) or
TLR3 (Meylan and Tschopp, 2005), and can bind directly
to NEMO (Hayden and Ghosh, 2004). Immunoprecipitation
of PIDD after different periods of activation at 37ºC revealed
that RIP1 and also NEMO were recruited to the PIDDosome
in a stimulus-dependent manner (Figure 1). In contrast, two
other known NF-kB intermediates, the RIP1-related protein
RIP2 and TRAF6, were not present in the PIDDosome, con-
firming the specificity of the PIDD-RIP1-NEMO interaction.
PIDD Is Necessary but Not Sufficient
for DNA-Damage-Induced NF-kB Activation
The above-mentioned results prompted us to investigate
whether the PIDDosome might be implicated in the activa-
tion of NF-kB. In contrast to RIP1, transient overexpression
of PIDD or RAIDD in HEK293T cells was not sufficient to in-
duce NF-kB activation, as measured by an NF-kB-depen-
dent reporter gene assay (Figure 2A). We previously noticed
that assembly of the PIDDosome is also not sufficient to in-
duce apoptosis but that a second signal (i.e., DNA damage)
is required for full commitment to caspase-2-mediated cell
death (Tinel and Tschopp, 2004). Hence, we tested whethernc.
cells stably expressing PIDD were sensitized for genotoxic-
stress-inducedNF-kBactivation. To this end,we tested topo-
isomerase I (CPT) as well as topoisomerase II (doxorubicin
[dox] and etoposide [eto]) targeting poisons. Although they
all lead to the formation of double-strand breaks and, con-
comitantly, activation of ATM (Avemann et al., 1988; Brom-
berg et al., 2003; Tewey et al., 1984), they can induce differ-
ent NF-kB responses. While particularly etoposide is known
to activate NF-kB transcriptional responses, doxorubicin is
known to be a weak inducer of NF-kB transcriptional activity
and might in certain cell types even lead to a repression of
NF-kB-dependent gene transcription (Campbell et al.,
2004; Huang et al., 2000). However, its potential to activate
the NF-kB pathway can easily be demonstrated at the level
of IkB phosphorylation or NF-kB DNA binding. As can be
seen in Figure 2B and Figure S1A in the Supplemental
Data available with this article online, HEK293T cells stably
expressing PIDD showed enhanced NF-kB transcriptional
activation upon stimulation with these different genotoxic
agents. This increased activation of the NF-kB signaling cas-
cade was also detected at the level of IkB phosphorylation
(Figure 2C; see also below). In comparison with mock-trans-
fected cells, cells stably expressing PIDD showed a slightly
Figure 1. The PIDDosome Incorporates NF-kB Signaling
Components
HEK293T cells stably expressing Flag-PIDD were lysed under hypotonic
conditions and incubated for the indicated times at 37ºC to allow sponta-
neous formation of the PIDDosome complex. Anti-Flag-PIDD immuno-
precipitates were analyzed for the presence of caspase-2, RIP1,
NEMO, TRAF6, RIP2, FADD, and Flag-PIDD byWestern blot. *represents
an unspecific band recognized by the FADD antibody. IP, immunopreci-
pitates; TL, total cell lysate.Cellincreased basal phosphorylation of IkB, and maximal levels
of IkB phosphorylation upon etoposide treatment were
reached more rapidly. The stimulating effect of PIDD on
the NF-kB pathway was not restricted to HEK293T cells
but was also observed in HeLa cells that had been stimu-
lated with either etoposide or doxorubicin (Figure S1B). Fur-
thermore, knockdown of endogenous PIDD levels in
HEK293T cells through the use of siRNA led to a substantial
inhibition of etoposide-induced phosphorylation of IkB
(Figure 2D and Figure 3C) and impaired NF-kB DNA binding
(Figure 2E and Figure S1E). As a result, we could not detect
an augmentation of Bcl-xL or XIAP mRNA, which are both
known to be NF-kB target genes (Figure 2F). The inhibitory
effect of PIDD siRNA treatment on NF-kB activation was
also observed in other cell types, such as U2OS cells (see
below), or with other genotoxic agents, such as CPT or
doxorubicin (see below and Figure S1C). Importantly, knock-
down of PIDD expression did not cause a general block in
the DNA-damage response as ATMwas still phosphorylated
upon etoposide stimulation (Figure S1D). Taken together,
these results identify PIDD as a crucial component of the
genotoxic-stress-triggered signaling pathway that leads to
NF-kB activation.
PIDD Causes Modification of NEMO
To further investigate how PIDDmight be implicated in geno-
toxic stress signaling, we analyzed endogenous NEMO
protein modifications induced by DNA damage. Confirming
previous results (Huang et al., 2003), we found that NEMO
became sumoylated in a time-dependent manner in re-
sponse to etoposide or doxorubicin (Figure 3A, left panel).
However, the amount of modified NEMO was marginal,
which correlates with the data of Huang that causes these
authors and others to speculate that NEMO is rapidly desu-
moylated once it is recognized by the ATM scaffold (Hay,
2004; Huang et al., 2003). Quite strikingly, the modified
form of NEMOwasmuchmore apparent in PIDD-expressing
cells than in mock cells (Figure 3A, right panel). To prove that
this modification was indeed a sumoylated form of NEMO,
we prepared lysates of nontreated, TNF-, or etoposide-
treated mock and PIDD-expressing cells; immunoprecipi-
tated NEMO under conditions designed to prevent associa-
tion with other interacting proteins; and monitored SUMO-1
(hereafter called SUMO) modification (Figure 3B). In PIDD-
expressing cells, endogenous SUMO-modified NEMO was
readily detected upon genotoxic stress but not upon TNF
stimulation. These experiments therefore indicate a role for
PIDD in the initial modification step of NEMO. Again in agree-
ment with the data of Huang et al., NEMO was not only su-
moylated but also ubiquitinated. Ubiquitination of NEMO
upon DNA damage was more readily detectable in PIDD-
expressing cells compared to mock cells (Figure 3B). This is
not surprising as sumoylation of NEMO appears to be a pre-
requisite for its subsequent ubiquitination (Huang et al.,
2003).
There is accumulating evidence that NEMO is polyubiqui-
tinated in response to different stimuli, inducing the activa-
tion of the IKKs rather than its proteasome-mediated degra-
dation (Burns and Martinon, 2004). Intriguingly, different123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1081
Figure 2. PIDD Is Necessary but Not Sufficient for DNA-Damage-Induced NF-kB Activation
(A) Overexpression of PIDD does not induce NF-kB activation. HEK293T cells were transiently transfected with expression vectors encoding PIDD, RAIDD,
caspase-2, or RIP1 combined with an NF-kB-dependent luciferase reporter gene and a b-galactosidase internal reporter. Luciferase activity in cell extracts
was normalized for differences in transfection efficiency on the basis of b-galactosidase activity. Values are the mean (± standard deviation) of three different
transfections and are expressed as fold induction relative to the mock (empty vector) control.
(B) HEK293T cells stably expressing PIDD are sensitized for DNA-damage-induced NF-kB activation. Mock-transfected cells (white bars) or PIDD-express-
ing cells (black bars) were stimulated for 16 hr with 50 mMCPT, 40 mM etoposide (Eto), or 2 mg/ml doxorubicin (Dox). NF-kB activation was evaluated using
the luciferase reporter gene assay. Values are the mean (± standard deviation) of three different transfections and are expressed as fold induction relative to
unstimulated cells.
(C) Etoposide-induced phosphorylation of IkB occurs faster and reaches higher maximal levels in PIDD stable cells. Mock-transfected cells or PIDD-
expressing cells were stimulated for the indicated times with 40 mM etoposide, lysed, and analyzed for phospho-IkB and Flag-PIDD levels. Caspase-3
was used as a loading control.
(D) siRNA against PIDD blocks genotoxic-stress-induced NF-kB activation. HEK293T cells were transfected with siRNA constructs for PIDD or a scrambled
control. Forty-eight hours after transfection, cells were stimulated for the indicated times with 40 mM etoposide and analyzed for phospho-IkB and PIDD
levels by Western blot. *represents an unspecific band, recognized by the mouse secondary antibody, which demonstrates equal loading.
(E) siRNA against PIDD abrogates etoposide-induced NF-kB DNA binding. HEK293T cells were transfected with siRNA for PIDD or a scrambled control.
Forty-eight hours after transfection, cells were stimulated for three hours with 40 mM etoposide and analyzed for NF-kB DNA binding by an EMSA (gel shift)
assay. In the third lane, a control reaction is shown in which we incubated a lysate of an etoposide-treated sample with a mutant NF-kB probe. Cytosolic
extracts were verified for PIDD expression.
(F) siRNA against PIDD blocks etoposide-induced expression of NF-kB-dependent genes. U2OS cells were transfected with siRNA constructs targeting
PIDD or a scrambled control. Forty-eight hours after transfection, cells were stimulated for the indicated times with 40 mM etoposide and analyzed for
the expression levels of Bcl-xL, XIAP, and actin mRNA by RT-PCR.1082 Cell 123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc.
agents induce different ubiquitin profiles, most likely provid-
ing a means for NEMO to integrate various responses via the
recruitment of specific ubiquitin binding proteins. TNF is
one of the agents that induce NEMO ubiquitination. How-
ever, we could not detect any augmentation of the TNF-
induced NEMO ubiquitin signal in PIDD-expressing cells
(Figure 3B), arguing against a general role for PIDD in
NEMO modification. We next checked whether knockdown
of PIDD interfered with genotoxic-stress-induced NEMO
modification. As can be seen in Figure 3C, siRNA against
PIDD abrogated etoposide- and doxorubicin-induced su-
moylation of NEMO, leading to a reduction in genotoxic-
stress-induced phosphorylation of NEMO, which is thought
to be induced in a subsequent step, through the action of
ATM (Huang et al., 2003). Concomitantly, phosphorylation
of IkB was impaired in PIDD siRNA-treated cells. SiRNA
treatment against RAIDD did not have such effects. Rather,
genotoxic-stress-induced modifications of NEMO appeared
to be slightly enhanced, leading to a stronger induction of
phospho-IkB (see also later). Finally, we immunoprecipitated
NEMO in conditions preventing association with other pro-
teins to evaluate sumoylation and ubiquitination of NEMO
(Figure 3D). In keeping with the data from Figure 3B, we
only detected very faint SUMO signals under these condi-
tions (which again appeared to be less in PIDD siRNA-
treated cells; data not shown), while we could easily observe
a strong inhibitory effect of PIDD siRNA on doxorubicin-
induced ubiquitination of NEMO. In conclusion, downregula-
tion of endogenous PIDD levels leads to a strong inhibition of
NEMO sumoylation, phosphorylation, and ubiquitination in
response to genotoxic stress, thus explaining the impaired
NF-kB response.
RIP1 Is Required for the Recruitment of NEMO to PIDD
PIDD interacts not only with the NF-kB signaling intermedi-
ate NEMO but also with RIP1 upon in vitro PIDDosome acti-
vation (see Figure 1). Interestingly, RIP1 was previously
shown to be essential for genotoxic-stress-induced signal-
ing to NF-kB (Hur et al., 2003), although its exact function
and/or position in the pathway remained unclear. We there-
fore generated Jurkat cells derived from either RIP1-wt or
RIP1-deficient clones that stably express PIDD. Subsequent
to genotoxic stress or TNF stimulation, endogenous NEMO
was immunoprecipitated under stringent conditions to pre-
vent association with other interacting proteins. Sumoylation
and ubiquitination of NEMO were only detectable in cells
expressing PIDD derived from RIP1-wt but not from RIP1-
deficient cells (Figure 4A), and this only upon genotoxic
stress. Confirming our previous results (Figure 3), the in-
creased sumoylation and ubiquitination of NEMO correlated
with a strongly enhanced activation of the NF-kB pathway
(Figure 4A).
To further characterize the role of RIP1 in PIDD-induced
sumoylation of NEMO, we analyzed in vitro PIDDosome
complex formation in lysates prepared from RIP1-wt or
RIP1-deficient PIDD-expressing Jurkat cells. NEMO recruit-
ment to PIDD was only detected in RIP1-wt but not in RIP1-
deficient cells, indicating that RIP1 mediates the interaction
of PIDD with NEMO (Figure 4B). Interestingly, more RAIDDCelland caspase-2 were recruited to PIDD in RIP1-deficient cells
(Figure 4B). Moreover, caspase-2 cleavage was much more
apparent inRIP1-deficient cells, suggesting ahyperactivation
of the PIDD-RAIDD-caspase-2 pathway in the absence of
RIP1.
The PIDD-RIP1-NEMO complex was not only formed
in vitro but also assembled in PIDD-expressing cells upon
genotoxic stress (Figure 4C). Interestingly, preferentially
SUMO-modified NEMO was detected in the assembling
PIDDosome, while the unmodified form of NEMO was barely
discernible in PIDD immunoprecipitates. This is in contrast
to the in vitro assay, where only the 47 kDa unmodified
form of NEMOwas detected (Figure 4B), indicating that incu-
bation of hypotonic lysates at 37ºC is sufficient to trigger
PIDDosome formation but not NEMO modification. This is
in keeping with the observation that phosphorylation of IkB
is not detectable in the in vitro assembly assay (Figure 4B,
lower panel). Thus, the mere formation of a complex be-
tween PIDD, RIP1, and NEMO is not sufficient to induce
NEMO sumoylation and the subsequent activation of NF-kB.
PIDD Shuttles to the Nucleus in Response
to Genotoxic Stress
In unstimulated cells, PIDD was localized predominantly in
the cytoplasm (Figure 5A). However, when cells were treated
with leptomycin B, a known inhibitor of the nuclear export
protein CRM1 (Fukuda et al., 1997), PIDD accumulated in
the nucleus, demonstrating that PIDD can shuttle between
cytosol and nucleus (Figure 5A). Genotoxic stimuli such as
CPT and doxorubicin, but not TNF, also led to nuclear accu-
mulation of a small portion of PIDD (Figure 5B and Figure S2).
Biochemical fractionation experiments yielded similar re-
sults. Upon genotoxic stress, cytosolic PIDD levels declined,
while nuclear PIDD levels increased (Figure 5C). In contrast,
we could not detect any translocation of RIP1 or NEMO to
the nucleus. As is apparent from Figure 5C, a substantial
portion of both RIP1 and NEMO was already present in the
nucleus in unstimulated cells, and the ratio between nuclear
and cytoplasmic levels was unaffected upon induction of
DNA damage. Of note, genotoxic-stress-induced sumoyla-
tion of NEMO was only detected in the nucleus. Additionally,
we observed that the nuclear fraction of NEMO exhibited
a slightly higher molecular mass and migrated as a doublet.
This modification was independent of the genotoxic stress
signals applied. Interestingly, the other PIDD-interacting pro-
tein, RIP1, was also modified exclusively in the nuclear frac-
tion. While the nature of this modification is currently not
known, these results show that, upon genotoxic stress,
a portion of PIDD accumulates in the nucleus where modifi-
cation of RIP1 and NEMO is observed.
PIDD-Induced NF-kB and Apoptosis Pathways
Are Independent
A role for caspase-2 in NF-kB activation was recently
proposed (Lamkanfi et al., 2005). As shown in Figure 2A,
we also consistently observed a small NF-kB activating
potential mediated by caspase-2 upon overexpression
in cells. However, neither siRNA against endogenous
caspase-2 nor siRNA against endogenous RAIDD affected123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1083
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genotoxic-stress-induced NF-kB activation (Figure 6A and
Figure 3C), making a physiologically relevant role for cas-
pase-2 or RAIDD in DNA-damage-induced activation of
NF-kB unlikely. These data led us to envisage the possibility
that PIDD acts as a docking platform, either interacting with
a survival complex consisting of the NF-kB signaling proteins
RIP1 and NEMO or interacting with a death-inducing com-
plex consisting of RAIDD and caspase-2. To strengthen
this hypothesis, we tested whether RIP1 and RAIDD could
interact simultaneously with PIDD. Figure 6B shows that in-
creasing amounts of RAIDD competed with RIP1 for binding
to PIDD and vice versa, strongly suggesting that RAIDD and
RIP1 interact in a mutually exclusive manner with PIDD. This
is in agreement with data shown in Figure 4B, where, in
RIP1-deficient cells, more RAIDD and caspase-2 were
found to interact with PIDD upon in vitro formation of the
PIDDosome. Furthermore, more caspase-2 was cleaved in
the absence of RIP1 (Figure 4B), suggesting a hyperacti-
vation of the PIDD-RAIDD-caspase-2 pathway. Alternatively,
when RAIDD levels were downregulated by siRNA treatment
(such as shown in Figure 3C), thereby blocking the PIDD
proapoptotic pathway, genotoxic agents induced a stronger
SUMO modification of NEMO, leading to an exacerbation
of the PIDD NF-kB pathway. Finally, we analyzed in vitro
PIDDosome assembly at early time points to possibly detect
a difference in kinetics for RIP1 and RAIDD recruitment to
PIDD. As can be seen in Figure 6C, RIP1 and NEMO were
recruited almost immediately to PIDD, while RAIDD and
caspase-2 were detectable only at later time points, sug-
gesting a sequential recruitment of the two complexes.
DISCUSSION
The death-domain protein PIDD was originally identified
as an early p53-inducible gene that is implicated in p53-
induced apoptosis (Lin et al., 2000). Cells stably expressing
PIDD are strongly sensitized for genotoxic-stress-induced
apoptosis through the formation of a so-called PIDDosome,
which contains the adaptor protein RAIDD and caspase-2
and triggers the mitochondrial pathway of apoptosis (Tinel
and Tschopp, 2004). In the present study, we confirm the
critical role for PIDD as a mediator of the DNA-damage-acti-
vated stress response and show its additional involvement in
genotoxic-stress-induced NF-kB activation.CellThe signals that relay nuclear DNA damage to the activa-
tion of cytoplasmic IKK complex and thus NF-kB are still
poorly defined. Only recently, Huang et al. discovered that
posttranslational modifications of NEMO play a central role
in this process (Huang et al., 2003). Two separate, parallel
pathways are needed to permit NEMO modifications. A first
pathway, induced by a so far unidentified signaling cascade,
leads to NEMO sumoylation and, as a consequence, its nu-
clear retention, while a second, ATM-dependent pathway
results in NEMO phosphorylation and subsequent ubiquiti-
nation. This allows NEMO to be released from the nucleus
and to activate the cytoplasmic IKK complex (Hay, 2004;
Huang et al., 2003). This two-way model is supported by
the observation that artificial SUMO attachment to NEMO
is not sufficient to induce NF-kB activation; neither is overex-
pression of ATM, showing the requirement of both signals.
In this study, we have identified PIDD as an essential com-
ponent in the pathway that leads to DNA-damage-mediated
NEMO sumoylation. Increased PIDD expression results in
highly augmented levels of SUMO-modified NEMO, while
knockdown of PIDD inhibits this posttranslational modifica-
tion. As a consequence, NEMO phosphorylation and ubiqui-
tination are also affected. Sumoylation of target proteins is
frequently involved in the control of subcellular localization,
and numerous recent reports demonstrate a close link be-
tween sumoylation and nuclear retention (Endter et al.,
2001; Li et al., 2005; Rangasamy et al., 2000). This pre-
sumptive function of sumoylation appears to hold true for
NEMO since artificial fusion of NEMO to SUMO is sufficient
to induce its nuclear accumulation (Huang et al., 2003).
NF-kB activation upon genotoxic stress occurs faster and
is more persistent in the presence of this fusion construct,
suggesting that SUMO modification is a major rate-limiting
step. This correlates with our observation that NF-kB activa-
tion in response to genotoxic stress is augmented in PIDD-
expressing cells and attains its maximum level of activation
more rapidly (Figure 2C), an effect that is most likely due to
increased NEMO-SUMO levels. The effect of PIDD siRNA
treatment on the modification of NEMO appears to be stron-
ger than its effect on NF-kB activation, leaving the possibility
open that there are other redundant pathways operational
that lead to genotoxic-stress-induced NF-kB activation.
Given the complexity of sumoylation reactions, we can en-
visage several mechanisms that could explain the enhancedFigure 3. PIDD Induces Modification of NEMO
(A) PIDD-expressing cells show an enhancedmodification of NEMO upon induction of genotoxic stress. HEK293T cells stably expressing EV (mock) or PIDD
were stimulated for the indicated time periods with 40 mM etoposide or 2 mg/ml doxorubicin. Lysates were analyzed for the presence of NEMO by Western
blotting with a mouse anti-NEMO antibody.
(B) NEMO sumoylation and ubiquitination are induced in DNA-damage-treated PIDD-expressing cells. HEK293Tmock or PIDD stably expressing cells were
stimulated for 2 hr with 10 ng/ml TNF or 40 mMetoposide. Lysateswere prepared in RIPA/SDS buffer to avoid coimmunoprecipitation of interacting proteins,
immunoprecipitated with a rabbit anti-NEMO antibody, and evaluated for the presence of SUMO-1 and ubiquitin modification of NEMO.
(C) PIDD is essential for genotoxic-stress-induced SUMO modification and phosphorylation of NEMO. HEK293T cells were transfected with siRNA con-
structs targeting RAIDD, PIDD, or a scrambled control and stimulated with etoposide or doxorubicin or left untreated. NP40 lysates were immunoprecipi-
tated with a rabbit anti-NEMO antibody and evaluated byWestern blotting with amouse anti-NEMO antibody for detection of SUMO-modified or phosphor-
ylated NEMO species. Three different exposure times of the same blot are shown. Total cell lysates were also analyzed for phosphorylation of IkB.
* corresponds to NEMO species from a previous exposure and was used as a loading control.
(D) PIDD is essential for genotoxic-stress-induced ubiquitination of NEMO. HEK293T cells were transfected with siRNA constructs targeting RAIDD, PIDD,
or a scrambled control and stimulated with doxorubicin or left untreated. RIPA lysates were immunoprecipitated with a rabbit anti-NEMO antibody and eval-
uated by Western blotting with anti-ubiquitin antibody for detection of modified NEMO species.123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1085
Figure 4. RIP1 Is Required to Establish a Complex, Induced upon Genotoxic Stress, between PIDD and NEMO
(A) PIDD-enhanced modification of NEMO upon treatment with genotoxic stress is strictly dependent on the presence of RIP1. RIP1-wt (RIP1+/+) or RIP1-
deficient (RIP1/) Jurkat cells, either mock or PIDD transfected, were left untreated or stimulated for 2 hr with 10 ng/ml TNF or 40 mM etoposide. Lysates
were prepared in RIPA/SDS buffer to avoid coimmunoprecipitation of interacting proteins, immunoprecipitated with a rabbit anti-NEMO, and evaluated for
the presence of SUMO-1 and ubiquitin modification of NEMO. Total cell extracts (TL) were also analyzed for phospho-IkB.
(B) RIP1-wt (RIP1+/+) orRIP1-deficient (RIP1/) Jurkat cells stablyexpressingFlag-PIDDwere lysedunderhypotonic conditionsand incubated for the indicated
times at 37ºC to allow spontaneous formation of the PIDDosome complex. Anti-Flag-PIDD immunoprecipitates were analyzed for the presence of NEMO,
RIP1, caspase-2, RAIDD, or Flag-PIDD by Western blot. Total cell extracts (TL) were analyzed for phospho-IkB as well. *represents the heavy chain of IgG.
(C) PIDD, RIP1, and NEMO form a complex induced by genotoxic stress. HEK293T mock-transfected or PIDD-expressing cells were stimulated for the in-
dicated timeswith 40 mMetoposide. Anti-Flag-PIDD immunoprecipitates were analyzed for the presence of NEMOandRIP1 byWestern blot. *represents an
unspecific band recognized by the rabbit anti-NEMO antibody.sumoylation of NEMO. PIDDmay recruit a known or an as yet
unknown E3 ligase to NEMO, leading to its enhanced su-
moylation. Alternatively, PIDD could act as an E3 ligase itself1086 Cell 123, 1079–1092, December 16, 2005 ª2005 Elsevier Inand directly enhance sumoylation of NEMO. This possibility
is less likely, however, as NEMO is not modified when incor-
porated in the in vitro-assembled PIDDosome, suggestingc.
Figure 5. PIDD Translocates to the Nucleus in Response to Genotoxic Stress
(A) PIDD-expressing HEK293T cells were left untreated or were stimulated for 2 hr with leptomycin B (LMB). Confocal images show nuclear (blue, DRAQ5) or
PIDD (green, Alexa 488) staining.
(B) PIDD-expressing HEK293T cells were left untreated or were stimulated for 2 hr with 50 mMCPT, 2 mg/ml doxorubicin, or 10 ng/ml TNF. Confocal images
show nuclear (blue, DRAQ5) or PIDD (green, Alexa 488) staining.
(C) PIDD-expressing HEK293T cells were stimulated for the indicated time periods with 2 mg/ml doxorubicin. Cytosolic and nuclear fractions were prepared,
verified for purity by analyzing PARP and caspase-3 levels, and evaluated for the presence of Flag-PIDD, RIP1, and NEMO. *represents an unspecific band
recognized by the rabbit anti-NEMO antibody.that additional components, activated upon genotoxic
stress, are required. Another attractive possibility is that
PIDD could stabilize SUMO-modified NEMO from desumoy-
lation, akin to SUMO-modified RanGAP1, which is resistant
to SENP2 (a SUMO isopeptidase) only when complexed with
both RanBP2 and Ubc9 (Pichler and Melchior, 2002; Zhang
et al., 2002). As RanBP2 does not act as an E3 ligase for
RanGAP1, its SUMO-enhancing activity on RanGAP1 is
thought to be solely due to this stabilizing function (Pichler
and Melchior, 2002).
In addition to PIDD, RIP1 appears to play an essential role
in DNA-damage-induced NF-kB activation. RIP1 is known toCellbe recruited to the TNF-R1 signaling complex and to be in-
dispensable for NF-kB activation by TNF (Kelliher et al.,
1998). This raises the possibility that DNA-damage-induced
NF-kB occurs through activation of the TNF-R1 signaling
cascade. However, DNA-damage-inducedNF-kB activation
is unaltered in TNF-R1-deficient cells (Hur et al., 2003), and
NEMO sumoylation is not observed in TNF-induced NF-kB
activation (Figure 3B), indicating that RIP1 is also implicated
in pathways in addition to that triggered by TNF. Based on
our data, it is very likely that PIDD is positioned upstream
of RIP1 in the signaling cascade triggered by genotoxic
stress. Similar to TNF-R1, PIDD contains a DD that binds123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1087
Figure 6. PIDD-Induced NF-kB and Apoptosis Pathways Are Independent
(A) RAIDD and caspase-2 are not essential for genotoxic-stress-induced NF-kB activation. U2OS cells were transfected with siRNA constructs targeting
RAIDD, PIDD, caspase-2, or a scrambled control and, 48 hr after transfection, were stimulated with 2 mg/ml doxorubicin for 2 hr. Cell lysates were evaluated
for IkB degradation by Western blot analysis. Caspase-3 was used as a loading control.
(B) RAIDD and RIP1 compete for binding to PIDD. HEK293T cells were transiently transfected with fixed amounts of expression vectors encoding Flag-PIDD
and VSV-RIP1 and increasing amounts of VSV-RAIDD or vice versa. PIDD was immunoprecipitated from the lysates with anti-Flag antibodies, and coim-
munoprecipitating proteins were revealed by Western blotting. *corresponds to the IgG1 heavy-chain band. **indicates degradation product of RIP1.
(C) RAIDD and RIP1 are recruited to activated PIDD with different kinetics. HEK293T cells stably expressing Flag-PIDD were lysed under hypotonic con-
ditions and incubated for the indicated times at 37ºC, which leads to spontaneous formation of the PIDDosome complex. Anti-Flag-PIDD immunoprecipi-
tates were analyzed for the presence of RAIDD and RIP1 by Western blotting.1088 Cell 123, 1079–1092, December 16, 2005 ª2005 Elsevier Inc.
Figure 7. PIDD Acts as a Molecular
Switch, Controlling the Balance between
Life and Death upon DNA Damage
See text for details.to the DD of RIP1 (data not shown). In both signaling path-
ways, RIP1 is subsequently modified. While RIP1 is ubiquiti-
nated following treatment with TNF (Legler et al., 2003), the
modification of RIP1 caused by genotoxic stress (Figure 5C)
is currently unknown. RIP1 recruitment is required for PIDD-
NEMObinding andmodification, ultimately leading to the ac-
tivation of IKKs. In both pathways, ubiquitination of NEMO
appears to be a pivotal event for the activation of the IKK sig-
nalosome (Huang et al., 2003; Tang et al., 2003). Both path-
ways, however, are clearly distinct with respect to the site of
assembly. The TNF-R1 complex is formed at the cell mem-
brane, while data currently available suggest assembly of
the PIDDosome in the nucleus. We observed that a small
portion of the mostly cytoplasmic PIDD accumulates in the
nucleus upon DNA damage, where it can encounter RIP1
and NEMO that both appear to be evenly distributed in the
cytosolic and nuclear compartment.
The question arises as to how DNA damage is sensed by
PIDD, leading to complex formation. Based on the capacity
of LRRs to detect pathogen-associated molecular patterns
in various Toll-like receptors, it is very likely that the LRRs
of PIDD are implicated in binding directly or indirectly to a
protein that is activated in DNA-damaged cells. As the
PIDDosome spontaneously assembles in cell extracts, this
presumptive ‘‘signaling molecule’’ is likely to be activated
as well or exposed upon cell rupture. The future identification
of this molecule will contribute greatly to our understanding
of DNA-damage-induced stress.Cell 1In addition to RIP1 and NEMO, PIDD also complexes with
RAIDD and caspase-2. As our results show, the NF-kB and
apoptotic machineries are recruited to PIDD in a sequential
manner (early recruitment of RIP1-NEMO versus late recruit-
ment of RAIDD-caspase-2). Evidence for the existence of
two distinct signaling platforms comes from competition ex-
periments showing that RIP1 and RAIDD interact in a mutu-
ally exclusive manner with PIDD. Moreover, in cells lacking
RIP1, kinetics of caspase-2 activation is highly accelerated
(Figure 4C), suggesting that an active NF-kB pathway blocks
or delays the caspase-2-mediated death pathway. Finally,
siRNA against RAIDD or caspase-2 showed that these two
molecules are dispensable for genotoxic-stress-induced
NF-kB activation.
Although many questions concerning the PIDD-RIP1-
NEMO signaling pathway remain open, the following model
could explain how the PIDDosome might integrate DNA-
damage signals (Figure 7). In unstimulated cells, PIDD is
mainly cytoplasmic. Upon genotoxic stress, PIDD detects
a stress-related signal of currently unknown nature, which
causes its nuclear translocation and/or retention, allowing
PIDD to accumulate in the nucleus and interact with RIP1
and NEMO, both of which are already present in the nucleus.
NEMO sumoylation and RIP1 modification then ensue. In
parallel, genotoxic stress induces activation of the protein
kinase ATM, which phosphorylates sumoylated NEMO,
leading to ubiquitination, nuclear export of NEMO, and
subsequent IKK activation in the cytoplasm. As amply23, 1079–1092, December 16, 2005 ª2005 Elsevier Inc. 1089
documented, the majority of the substrates activated by
ATM are implicated in cell-cycle control and activation of
the p53 pathway or in DNA repair (Shiloh, 2003). Together,
these ATM-activated pathways allow the cell to repair dam-
age and restore normal growth unharmed. However, this
may not be always possible, and, in cases of excessive
DNA damage, an apoptotic program is induced to avoid
possible cellular transformation. In addition to PIDD, DNA-
damage-induced p53 transcriptional activity also leads to
the induction of several proapoptotic genes such as Bax,
Puma, or Noxa (Nakano and Vousden, 2001; Slee et al.,
2004; Villunger et al., 2003). De novo gene transcription of
PIDD and consequent activation of caspase-2, together
with the activation of the other p53-dependent proapoptotic
genes, eventually lead to the execution phase in which the
cell activates its own suicide program. This model predicts
that knockdown of PIDDwill not ablate p53-induced apopto-
sis, considering that the BH3 members Noxa or Puma can
induce mitochondrial damage independently of caspase-2.
Indeed, we found that reduced PIDD levels slightly increase
the sensitivity of cells to genotoxic-stress-induced apopto-
sis, which can be explained by decreased NF-kB activity
(Figure S3C). Just like p53, PIDD thus acts as a molecular
switch, able to activate a survival or apoptotic program.
The final outcome is probably determined by the type and
amount of damage to the genome and the overall physiolog-
ical state of the cell.
EXPERIMENTAL PROCEDURES
Cell Culture and Biological Reagents
Human embryonic kidney (HEK) cells, U2OS human osteosarcoma cells,
HeLa cells, and HEK293T cells stably expressing PIDD were grown in
DMEM and Glutamax (Life Technologies) supplemented with 10% fetal
calf serum and 100 U/ml penicillin, 100 mg/ml streptomycin. RIP1-wt
and RIP1-deficient Jurkat cells were grown in RPMI containing Glutamax
(Life Technologies) supplemented with 10% fetal calf serum and 100 U/ml
penicillin, 100 mg/ml streptomycin. The generation of cells stably express-
ing PIDD was described elsewhere (Tinel and Tschopp, 2004). Cells sta-
bly expressing PIDD were always compared to mock-transfected cells
(transfected with empty vector). Camptothecin, human recombinant




2-Flag, pCR3-RIP1-Flag, pCR3-RAIDD-VSV, and pCR3-RIP1-VSV have
been described previously (Tinel and Tschopp, 2004). pNFconluc, con-
taining the luciferase reporter gene driven by a minimal NF-kB-
responsive promoter, was a gift of Dr. A. Israel (Institut Pasteur, Paris).
pactbgal, containing the b-galactosidase gene under the control of the
b-actin promoter, was obtained fromDr. T. Inoue (Institute of Medical Sci-
ences, Tokyo).
Transient Transfections and NF-kB Reporter Gene Assays
HEK293T and HEK293 cells stably expressing PIDD or the empty vector
were transiently transfected by the DNA-calcium-phosphate precipitation
method with 100 ng pNFconluc, 100 ng pactßgal, and different concen-
trations of specific expression plasmids. The total amount of DNA was
kept constant by adding empty vector up to 1 mg DNA per six-well. NF-
kB activity was determined by measuring the luciferase activity present
in cell extracts. Luciferase values were normalized for differences in trans-
fection efficiency on the basis of b-galactosidase activity in the same ex-1090 Cell 123, 1079–1092, December 16, 2005 ª2005 Elsevier Intracts and expressed as fold induction values relative to the unstimulated
empty-vector control. Where needed, cells were stimulated 48 hr post-
transfection for 16 hr with 2 mg/ml doxorubicin, 40 mM etoposide, 50
mM camptothecin or left untreated.
Preparation and Transfection of siRNA
siRNA oligonucleotides against RAIDD (GGCCAGAGACAAACAAG
TACTC), PIDD (CAGACTGTTCCTGACCTCAGA), and caspase-2 (AAA
CAGCTGTTGTTGAGCGAA) were purchased fromQIAGEN. siRNA oligo-
nucleotides against RIP1 (GGCGAAGATGATGAACAGA) were obtained
from Ambion. A scrambled siRNA was used with sequence
GGTTCTTCAGTACCTCTACCA. HEK293T cells were transfected using
the calcium-phosphate precipitation technique. U2OS cells were trans-
fected using Oligofectamin (Invitrogen).
EMSA Assays
HEK293T cells were transfected with a siRNA control or a siRNA con-
struct targeting PIDD. Forty-eight hours after transfection, cells were stim-
ulated for different time periods with 40 mM etoposide. Nuclear fractions
were prepared as described elsewhere (Petrilli et al., 2004). 32P-labeled
double-stranded oligonucleotides containing the kB site from the Igk
gene were prepared as described by Miyamoto et al. (1994) (wt, 50-TCAA
CAGAGGGGACTTTCCGAGAGGCC-30; mutated, 50-TCAACAGAG
CTCACTTTATGAGAGGCC-30). DNA/nucleoprotein complexes were
separated from free probe on a 4% polyacrylamide gel.
RT-PCR
U2OS cells were transfected with a scrambled siRNA or siRNA against
PIDD. Forty-eight hours later, cells were treated for different time periods
with 40 mM etoposide. RNA was prepared with Trizol (Invitrogen), and 5
mg was used for a T-primed RT-PCR reaction (Amersham). Specific pri-
mers were used to amplify actin, XIAP (sense, TGGCAATATGGAGACT
CAGC; antisense, TGCACTTGGTCACCAATACC), or Bcl-xL (sense,
CATGGCAGCAGTAAAGCAAGCG; antisense, AGGCTCTAGGTGGTCA
TTCAGG).
In Vitro Activation and Immunoprecipitation
Preparation of the lysates in hypotonic buffer and in vitro activation and
immunoprecipitation were performed as described previously (Tinel and
Tschopp, 2004). Cells were washed twice with PBS and resuspended
in hypotonic buffer (20 mM HEPES-KOH, 10 mM KCl, 1 mMMgCl2, 1 mM
EDTA, 1mMEGTA, 1mMDTT [pH 7.5]) supplemented with protease inhib-
itors (Complete, Roche). Resuspended cells were lysed by using a 22G
needle. Cellular debris was removed by centrifugation at 10,000  g for
20 min at 4ºC followed by filtration at 0.4 mm. Clear lysates were incubated
at 37ºC for the indicated times or left untreated on ice. After incubation,
an equivalent volume of hypotonic buffer containing 0.1% NP-40 and
300 mM NaCl was added. The mix was incubated overnight with M2-Flag
beads (Sigma) at 4ºC on a rotating wheel.
Coimmunoprecipitation and Western Blotting
PIDD complexes were revealed after either in vitro activation for the indi-
cated times of lysates of PIDD-expressing cells and immunoprecipitation
of Flag-PIDD (see description before) or after activation of the cells by
treatment with 40 mM etoposide for different periods. Lysates were pre-
pared in E1A lysis buffer (1% NP-40, 20 mM HEPES [pH 7.9], 250 mM
NaCl, 20mM b-glycerophosphate, 10mMNaF, 1mM sodium orthovana-
date, 2 mM dithiothreitol, 1 mM EDTA, and a protease-inhibitor cocktail),
and Flag-PIDD was immunoprecipitated from cleared lysates with M2-
Flag beads (Sigma) at 4ºC on a rotating wheel. Sumoylated or ubiquiti-
nated forms of NEMO were detected by preparing lysates of stimulated
cells in RIPA buffer (25 mM Tris [pH 8.2], 50 mM NaCl, 0.5% NP-40,
0.5% deoxycholic acid, 0.1% SDS, 10 mM iodoacetate) supplemented
with protease and phosphatase inhibitors and sheared using a 22G nee-
dle. Cleared lysates were incubated overnight with a rabbit NEMO anti-
body that was preincubated with protein G Sepharose. Coimmunopreci-
pitation experiments with transfected proteins were done in E1A lysis
buffer. After lysis, the extracts were incubated with anti-Flag beads forc.
2 hr. After incubation, the beads were washed six times with lysis buffer,
separated by SDS-PAGE, transferred to nitrocellulose, and analyzed by
immunoblotting. Antibodies used were anti-IkB (Santa Cruz), anti-phos-
pho-IkB (Cell Signaling), rabbit anti-NEMO (Santa Cruz), mouse anti-
NEMO (Transduction Labs), anti-RIP1 (Transduction Labs), anti-FADD
(Transduction Labs), anti-TRAF6 (Santa Cruz), anti-RAIDD (MBL), anti-
RIP2 (Alexis), anti-caspase-2 11B4 (Apotech), anti-SUMO-1 (Zymed),
anti-ubiquitin (Santa Cruz), anti-Flag and anti-VSV (Sigma), anti-ATM
(Genetex), anti-P-ATM (Cell Signaling), anti-caspase-3 (Transduction
Labs), and anti-PARP (Cell Signaling). AL233 is a rabbit polyclonal anti-
body raised against PIDD-DD (776–910) by Eurogentec. 1G3-4F7 is
a monoclonal PIDD antibody raised against PIDD-DD (776–910).
Biochemical Fractionation
HEK293T cells stably expressing PIDD were treated with 2 mg/ml doxoru-
bicin for different time periods. Cytoplasmic and nuclear fractions were
prepared according to the protocol of Dignam et al. (1983). Briefly, cells
were lysed in a cytosolic lysis buffer containing 10 mM HEPES (pH 7.9),
1.5 mM MgCl2, 300 mM sucrose, 0.5% NP-40, 10 mM KCl supple-
mented with DTT and protease inhibitors. Nuclei were pelleted by a short
centrifugation and lysed in a nuclear buffer containing 20 mMHEPES (pH
7.9), 100 mM NaCl, 0.2 mM EDTA, 20% glycerol, 100 mM KCl supple-
mented with DTT and protease inhibitors. Nuclear pellets were subjected
to a freeze-thaw cycle, sonicated, and centrifuged to obtain a solubilized
nuclear fraction.
Immunostaining and Confocal Microscopy
PIDD stable HEK293T or EV cells were cultured on sterile glass coverslips
in six-well plates and fixed with a solution containing 1% paraformalde-
hyde, 2% glucose, and 5 mM azide in PBS for 15 min. Cells were perme-
abilized with 0.3% saponin for 10 min and treated with 2% normal goat
serum (NGS)/0.5% BSA/0.1% saponin as a blocking reagent. Flag anti-
body (M2, Sigma) was used at a dilution of 1/500 in 0.1% saponin/
0.1% BSA/PBS, while a secondary Alexa 488 anti-mouse IgG1 (Molecu-
lar Probes) was used at a dilution of 1/300 in 0.1% saponin/0.1% BSA/
PBS. Cells were mounted in FluorSave (Calbiochem) containing a 1/
1000 dilution of DRAQ5 (Alexis) for nuclear counterstain. Images from im-
munostaining were collected by using a Zeiss inverted laser scanning
confocal microscope LSM 510 with a 63 oil immersion objective.
Supplemental Data
Supplemental Data include three figures and can be found with this article
online at http://www.cell.com/cgi/content/full/123/6/1079/DC1/.
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